文献速递特殊人群用药药物相互作用药物不良反应与药物警戒

蒽环类化疗个体化给药是否还有改进空间?

Is there scope for better individualisation of anthracycline cancer chemotherapy?
PubMed 文献 · Br J Clin Pharmacol · 2020-11-30

蒽环类用于治疗实体瘤和血液肿瘤,骨髓抑制和心脏毒性是限制疗程和强度的主要毒性。累积剂量是心脏毒性风险的重要预测因素,提示药代动力学变异性可能起作用。儿童群体药代模型显示极低龄儿童多柔比星清除率显著低于年长儿童,基于体表面积和年龄的模型可能替代现行初始剂量选择工具;成人模型尚不足以支持临床应用,基因关联研究也缺乏可重复的临床显著关联。

要点

  • 累积蒽环剂量是心脏毒性风险的重要预测因素。
  • 极低龄儿童多柔比星清除率显著低于年长儿童。
  • 成人群体药代模型尚不足以支持临床精准给药。

核心结论

  • 蒽环类精准给药目前受限于缺乏临床可用的药代动力学目标和预测累积暴露的模型。
  • 未来经验证的目标和模型结合心脏毒性风险因素、高级超声和生物标志物,可能实现精准给药。

研究设计与样本

  • 本文为综述,总结蒽环类药代动力学变异与个体化给药的证据。

主要发现

  • 累积蒽环剂量是心脏毒性风险的显著预测因素,提示药代动力学变异的作用。
  • 儿童群体药代模型显示极低龄儿童多柔比星清除率显著低于年长儿童,可能贡献其更高的心脏毒性风险。
  • 基于体表面积和年龄的多柔比星清除率模型提供以患者为中心的剂量调整策略,可能替代现行不同的初始剂量选择工具。
  • 成人群体药代模型尚未充分处理高龄、肥胖、肝肾功能障碍和潜在药物相互作用以支持临床应用。
  • 候选基因和全基因组关联研究调查了遗传变异与蒽环药代或临床结局的关系,但临床显著可重复关联很少。

临床怎么用

  • 儿童<7岁可考虑基于体表面积和年龄的模型调整多柔比星初始剂量。
  • 成人蒽环给药需关注高龄、肥胖、肝肾功能和药物相互作用,但现有模型尚不足以指导精准调整。
  • 结合心脏毒性风险因素、高级超声和生物标志物进行风险分层管理。

局限性

  • 缺乏临床可用的药代动力学目标和预测累积蒽环暴露的模型。
  • 成人群体药代模型未充分覆盖高龄、肥胖、肝肾功能障碍和药物相互作用。
  • 遗传关联研究缺乏临床显著可重复的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anthracyclines are used to treat solid and haematological cancers, particularly breast cancers, lymphomas and childhood cancers. Myelosuppression and cardiotoxicity are the primary toxicities that limit treatment duration and/or intensity. Cardiotoxicity, particularly heart failure, is a leading cause of morbidity and mortality in cancer survivors. Cumulative anthracycline dose is a significant predictor of cardiotoxicity risk, suggesting a role for anthracycline pharmacokinetic variability. Population pharmacokinetic modelling in children has shown that doxorubicin clearance in the very young is significantly lower than in older children, potentially contributing to their higher risk of cardiotoxicity. A model of doxorubicin clearance based on body surface area and age offers a patient-centred dose-adjustment strategy that may replace the current disparate initial-dose selection tools, providing a rational way to compensate for pharmacokinetic variability in children aged <7 years. Population pharmacokinetic models in adults have not adequately addressed older ages, obesity, hepatic and renal dysfunction, and potential drug-drug interactions to enable clinical application. Although candidate gene and genome-wide association studies have investigated relationships between genetic variability and anthracycline pharmacokinetics or clinical outcomes, there have been few clinically significant reproducible associations. Precision-dosing of anthracyclines is currently hindered by lack of clinically useful pharmacokinetic targets and models that predict cumulative anthracycline exposures. Combined with known risk factors for cardiotoxicity, the use of advanced echocardiography and biomarkers, future validated pharmacokinetic targets and predictive models could facilitate anthracycline precision dosing that truly maximises efficacy and provides individualised early intervention with cardioprotective therapies in patients at risk of cardiotoxicity.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sallustio BC, Boddy AV. Is there scope for better individualisation of anthracycline cancer chemotherapy? Br J Clin Pharmacol. 2020. PMID: 33118175. doi:10.1111/bcp.14628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。